The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Sensitivity analyses for progression-free survival (PFS) and radiographic PFS (rPFS) from the phase II STRIVE trial comparing enzalutamide (ENZA) with bicalutamide (BIC) in men with castration-resistant prostate cancer (CRPC).
 
David F. Penson
Consulting or Advisory Role - Astellas Pharma; Medivation
Research Funding - Astellas Pharma (Inst); Medivation (Inst)
 
Andrew J. Armstrong
Honoraria - Dendreon; Sanofi
Consulting or Advisory Role - Bayer; Dendreon; Janssen Biotech; Medivation; Novartis; Sanofi
Speakers' Bureau - Dendreon
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); ImClone Systems (Inst); Janssen Oncology (Inst); KangLaiTe (Inst); Medivation (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture technology (Inst)
Travel, Accommodations, Expenses - Dendreon; Janssen Biotech; Medivation
 
Raoul S. Concepcion
Consulting or Advisory Role - Chan Soon-Shiong Institute for Advanced Health
Speakers' Bureau - Astellas Pharma; Bayer; Genomic Health; Janssen; Medivation
Research Funding - Astellas Pharma; Bayer; Genomic Health; Janssen; Medivation; Valeant/Dendreon
 
Kenneth Wu
Employment - Medivation
 
Fong Wang
Employment - Medivation
 
Andrew P. Krivoshik
Employment - Astellas Pharma
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie; Johnson & Johnson (I); Merck (I)
Patents, Royalties, Other Intellectual Property - U.S. Patent Application 20090149461 11 June 2009 Method of Treating Cancer (U.S. Provisional Application Ser. No. 61/058,113, filed Jun. 2, 2008; U.S. Provisional Application Ser. No. 60/992,857, filed Dec. 6, 2007). European Patent Office Application 08 (Inst)
Travel, Accommodations, Expenses - Astellas Pharma
 
De Phung
Employment - Astellas Pharma
 
Celestia S. Higano
Employment - Cell Therapeutics (I)
Leadership - Cell Therapeutics (I)
Stock and Other Ownership Interests - Cell Therapeutics (I)
Consulting or Advisory Role - AbbVie; Bayer; BHR Pharma; Dendreon; Emergent BioSolutions; Ferring; Genentech; Medivation; Orion; Pfizer; Sanofi
Research Funding - Algeta/Bayer (Inst); Aragon Pharmaceuticals (Inst); AstraZeneca (Inst); Dendreon (Inst); Emergent BioSolutions (Inst); Exelixis (Inst); Genentech (Inst); Medivation (Inst); Millennium (Inst); Oncogenex (Inst); Sanofi (Inst); Teva (Inst)
Travel, Accommodations, Expenses - AbbVie; Amgen; Astellas Pharma; Bayer; Dendreon; Emergent BioSolutions; Ferring; Genentech; Johnson & Johnson; Medivation; Ockham; Orion; Pfizer; Sanofi; Teva